Waters Corporation (NYSE:WAT) is one of the 10 Best Diagnostics and Research Stocks to Buy According to Analysts. Waters (WAT) Prices $3.5 Billion Senior Notes Offering On March 18, 2026, Waters Corporation (NYSE:WAT) announced the pricing of a $3.5 billion senior notes offering through its subsidiary, Augusta SpinCo Corporation. The multi-tranche issuance features interest rates ranging from 4.321% to 5.245%.  Their maturities span from 2027 to 2036. The offering is expected to close around March 23, 20 ...

Waters Corporation (WAT) is a leading scientific instruments company that designs, manufactures, and markets advanced analytical technologies, including high-performance liquid chromatography, mass spectrometry, thermal analysis, rheometry, and related software and consumables used in laboratory research, quality assurance, and industrial applications across life sciences, pharmaceutical, food safety, environmental, and academic sectors. Headquartered in Milford, Massachusetts, Waters has built a global pr ...

Waters Prices Offering of Senior Notes Accessibility StatementSkip Navigation MILFORD, Mass., March 18, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) (the "Company" or "Waters") today announced that it has priced an offering (the "Offering") of $3.5 billion aggregate principal amount of the following senior notes issued by its subsidiary, Augusta SpinCo Corporation ("Augusta"): The Offering is expected to close on or about March 23, 2026, subject to the satisfaction of customary closing conditions. Th ...

Core Insights - Redfin estimates that allowing home sellers to test pricing strategies before listing could increase housing inventory by 6%-12% in certain markets, enhancing buyer options and potentially leading to more transactions [1] Group 1: Housing Inventory and Market Dynamics - The flexibility for sellers to use 'Private Exclusive' and 'Coming Soon' listings allows them to gauge interest and determine accurate pricing, which can lead to a more confident decision to list their homes [1] - Redfin's analysis indicates that phased marketing can help sellers avoid prolonged market times and price cuts, which are detrimental to home sales [1] - The report highlights that overpricing a home by 10% or more can extend the time it remains on the market by over a month, emphasizing the importance of accurate pricing [1] Group 2: Seller Benefits and Market Confidence - Phased marketing offers sellers privacy and convenience, allowing them to market their homes without extensive public exposure, which is particularly appealing to certain demographics [1] - Sellers utilizing phased marketing are less likely to experience price cuts, which can negatively impact buyer perception and final sale prices [1] - The report suggests that as more homeowners feel empowered to list their properties, the overall housing inventory will increase, addressing the current housing shortage [1]

Core Viewpoint - Waters Corporation has reported strong fourth-quarter earnings, surpassing estimates, but the stock has seen a decline of approximately 8.4% since the last earnings report, underperforming the S&P 500 [1] Financial Performance - Waters reported Q4 2025 non-GAAP earnings of $4.53 per share, exceeding the Zacks Consensus Estimate by 0.67% and reflecting a year-over-year increase of 10.5% [2] - Net sales reached $932.4 million, surpassing the Zacks Consensus Estimate by 0.55%, with a reported increase of 7% year-over-year and 6% on a constant currency basis [2] Segment Performance - The Waters segment generated sales of $823.9 million, up 8% on a reported basis and 7% on a constant currency basis year-over-year, while the TA segment reported flat sales of $108.4 million [3] - Instrument sales were $432.9 million, up 3% year-over-year, Services sales were $329.1 million, increasing 9%, and Chemistry sales were $170.3 million, growing 13% [4] Market Performance - The Pharmaceutical market generated sales of $540.6 million, an 8% increase year-over-year, while Industrial sales were $284.5 million, also up 8%. Government & Academic sales decreased by 2% to $107.3 million [5] - Sales by region included $283.9 million from Asia (up 4%), $332.4 million from the Americas (up 4%), and $315.9 million from Europe (up 13% reported) [6] Operating Expenses - Non-GAAP selling and administrative expenses were $191 million, up 13.3% year-over-year, with an adjusted operating margin of 35.2%, contracting 20 basis points [7] Balance Sheet and Cash Flow - As of December 31, 2025, cash and cash equivalents were $587.8 million, up from $459.1 million in September. The company generated cash from operations of $164.5 million and reported free cash flow of $125.2 million [8] Guidance - For Q1 2026, Waters expects sales growth between 7% and 9% on a constant currency basis, with projected sales of $718-$731 million on an organic reported basis [10] - For FY 2026, the company anticipates constant currency sales growth of 5.5% to 7%, with expected non-GAAP earnings in the range of $14.30 to $14.50 per share, reflecting year-over-year growth of approximately 8.9% to 10.4% [11] Estimate Revisions - Since the earnings release, there has been a downward trend in estimates, with the consensus estimate shifting down by 9.42% [12] VGM Scores - Waters has a subpar Growth Score of D and a Momentum Score of C, with an overall aggregate VGM Score of D, indicating it is in the bottom 40% for value investors [13] Industry Comparison - Waters is part of the Zacks Medical - Instruments industry, where competitor Hologic reported revenues of $1.05 billion, reflecting a year-over-year change of +2.5% [15]

Core Viewpoint - Waters Corporation (WAT) is positioned favorably following a significant acquisition of the Biosciences & Diagnostics Solutions business, indicating a positive outlook for the company towards the end of 2025 [1]. Group 1 - The investment group, Value In Corporate Events, has identified Waters as being in "calmer waters" after the acquisition, suggesting stability and potential growth opportunities for investors [1]. - The group focuses on capitalizing on major corporate events such as IPOs, mergers & acquisitions, and earnings reports, with a coverage of 10 significant events monthly [1].

Core Insights - Waters Corporation launched the ARES-G3 Rheometer, which sets a new benchmark for data quality and speed in materials research and product development [1] Product Features - The ARES-G3 Rheometer operates with fewer calibrations and superior atmosphere and temperature control [1] - It delivers an industry-leading 25,000 data points per second, which is 10 times more than its predecessor [1] - The device reduces standard testing times by up to 80%, with some tests being shortened from six hours to one [1] Industry Impact - The ARES-G3 Rheometer addresses significant industry limitations by enabling scientists to capture transient material behaviors that were previously undetectable [1] - It allows for increased lab throughput and the ability to perform many tests without requiring user calibrations, thus reducing human error [1] Technological Advancements - The integration of Fast Frequency Chirps and enhanced TRIOS Software simplifies data capture and processing, eliminating the need for multiple software licenses [1] - The new rheometer retains the best-in-class oven of the ARES-G2 Rheometer, providing leading low-oxygen atmosphere control and temperature uniformity [1] Compatibility and Availability - All existing ARES-G2 Rheometer methods and fixtures are fully compatible with the ARES-G3 Rheometer [1] - The ARES-G3 Rheometer is available for order immediately [1]

Core Viewpoint - Waters (WAT) has received an upgrade to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on the Zacks Consensus Estimate, which reflects EPS estimates from sell-side analysts for the current and following years [1]. - Changes in a company's future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements [4]. - Institutional investors often rely on earnings estimates to determine the fair value of a company's shares, leading to buying or selling actions that affect stock prices [4]. Improvement in Business Outlook - The rising earnings estimates and the Zacks rating upgrade for Waters suggest an improvement in the company's underlying business, which could lead to increased stock prices as investors respond positively [5]. - Over the past three months, the Zacks Consensus Estimate for Waters has increased by 1%, with expected earnings of $14.40 per share for the fiscal year ending December 2026, indicating no year-over-year change [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - The upgrade of Waters to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

Core Viewpoint - Berkshire Hathaway's shares experienced their largest decline since the announcement of Warren Buffett's succession plan, following disappointing financial results and cautious investment outlook from the company [1]. Financial Performance - In the fourth quarter, Berkshire Hathaway reported an operating profit of $10.2 billion, marking a 30% decrease compared to the previous year, with Geico and other insurance businesses seeing a 38% decline [2]. - Analyst Meyer Shields noted that the results broadly missed forecasts, reflecting weaknesses in various sectors including BNSF railroad, energy, manufacturing, and retail, leading to a 5% reduction in his 2026 earnings forecast for the company [4]. Strategic Outlook - Greg Abel, in his first annual letter to shareholders, indicated that Geico may continue to face challenges in retaining customers due to competitive pricing pressures, while other insurance operations are also experiencing pricing pressures from increased capital in the market [3]. - Despite holding a significant cash stake of $373 billion, Abel emphasized a careful assessment of value and a long-term investment strategy, without indicating plans for stock buybacks or dividends [3].